FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007650562> ?p ?o ?g. }

• W2007650562 endingPage "614" @default.
• W2007650562 startingPage "614" @default.
• W2007650562 abstract "Abstract Elevated AR expression or mutations in tumor cells, causing resistance to first generation AR antagonist agents, are considered the main driver of castration resistant prostate cancer (CRPC). MDV3100, a more potent AR antagonist ( 5x vs bicalutamide) without residual agonism, has demonstrated excellent efficacy in CRPC patients and has been approved by FDA for treating CRPC in clinic. More recently, AR antagonists demonstrated anti-tumor activities in preclinical AR+ breast cancer models and are being tested in clinical trials. Although MDV3100 is generally well-tolerated, there is a need to eliminate the clinically observed CNS AE's ( 1% incidences of seizure) and revserse the resistance to MDV3100 in CRPC patients. Suzhou Kintor previously reported a preclinical candidate compound Proxalutamide (GT0918), a potent androgen receptor (AR) antagonist with ability to down regulate AR protein level in prostate cancer cells. In biochemical assay, GT0918 more potently inhibits androgen binding with AR's ligand binding domain than Bicalutamide (11.4x) and MDV3100(3.5x). In both hormone-sensitive (LNCaP) and CRPC (C4-2) cancer cells, GT0918 demonstrated stronger potency to block AR function of gene transcription than Bicalutamide (∼5-10) and MDV3100(2-5x) while maintaining full antagonism in CRPC cells. GT0918 impairs androgen stimulated AR translocation to cell nuclei hence blocks its binding DNA and shuts down the downstream oncogenic signaling. Moreover, GT0918 induced AR down regulation in prostate cancer cells. As the AR up-regulation remains to be the main driver of CRPC resistance, its feature of AR down regulation may enable GT0918 to retain efficacy against CRPC that have developed resistance to current AR-blockage treatments. In vitro, GT0918 not only inhibits proliferation of hormone-sensitive CaP cells, but also more potently inhibits proliferation of CRPC cells than MDV3100 (6.5x). In addition, GT0918 inhibits the growth of AR positive breast cancer cells. In contrast, GT0918 has minimum effects on the growth of AR-negative CaP cells (PC-3 and DU145), indicating it is a selective AR pathway inhibitor. In vivo, GT0918 demonstrated good anti-tumor efficacy among hormone sensitive, CRPC and AR+ breast cancer animal models with efficacious drug exposure lower than MDV3100. ADME profile was optimized for once a day dosing schedule in human to reduce drug accumulation as seen in MDV3100. IND-enabling GLP toxicology studies have been completed for GT0918, which was well-tolerated with minimum safety findings except for the effects expected from anti-androgens. Toxicokinetic studies confirmed the drug exposures in toxicology studies were significantly higher (rat: 11; dog: 25x) than the exposure required for maximum efficacy. No seizure was observed across all the animal safety studies. An IND application has been filed for starting Phase I clinical trial to test the selective AR pathway blocker GT0918 in patients. Citation Format: Youzhi Tong, Chunyun Chen, Juan Wu, Jiangtao Yang, Huihui Zhang, Xiaojun Wu, Yanmei Duan, Wei Gao, Weidong Qian, Xiaoxia Niu, Lili Mi, Chuangxing Guo. Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 614. doi:10.1158/1538-7445.AM2014-614" @default.
• W2007650562 created "2016-06-24" @default.
• W2007650562 creator A5013087679 @default.
• W2007650562 creator A5023418418 @default.
• W2007650562 creator A5025633795 @default.
• W2007650562 creator A5041593666 @default.
• W2007650562 creator A5046889179 @default.
• W2007650562 creator A5047287213 @default.
• W2007650562 creator A5056802565 @default.
• W2007650562 creator A5060562759 @default.
• W2007650562 creator A5065843964 @default.
• W2007650562 creator A5073345216 @default.
• W2007650562 creator A5076296458 @default.
• W2007650562 creator A5081351589 @default.
• W2007650562 date "2014-10-01" @default.
• W2007650562 modified "2023-09-24" @default.
• W2007650562 title "Abstract 614: Proxalutamide (GT0918), a potent androgen receptor pathway inhibitor" @default.
• W2007650562 doi "https://doi.org/10.1158/1538-7445.am2014-614" @default.
• W2007650562 hasPublicationYear "2014" @default.
• W2007650562 type Work @default.
• W2007650562 sameAs 2007650562 @default.
• W2007650562 citedByCount "11" @default.
• W2007650562 countsByYear W20076505622018 @default.
• W2007650562 countsByYear W20076505622019 @default.
• W2007650562 countsByYear W20076505622020 @default.
• W2007650562 countsByYear W20076505622021 @default.
• W2007650562 countsByYear W20076505622022 @default.
• W2007650562 countsByYear W20076505622023 @default.
• W2007650562 crossrefType "journal-article" @default.
• W2007650562 hasAuthorship W2007650562A5013087679 @default.
• W2007650562 hasAuthorship W2007650562A5023418418 @default.
• W2007650562 hasAuthorship W2007650562A5025633795 @default.
• W2007650562 hasAuthorship W2007650562A5041593666 @default.
• W2007650562 hasAuthorship W2007650562A5046889179 @default.
• W2007650562 hasAuthorship W2007650562A5047287213 @default.
• W2007650562 hasAuthorship W2007650562A5056802565 @default.
• W2007650562 hasAuthorship W2007650562A5060562759 @default.
• W2007650562 hasAuthorship W2007650562A5065843964 @default.
• W2007650562 hasAuthorship W2007650562A5073345216 @default.
• W2007650562 hasAuthorship W2007650562A5076296458 @default.
• W2007650562 hasAuthorship W2007650562A5081351589 @default.
• W2007650562 hasConcept C121608353 @default.
• W2007650562 hasConcept C126322002 @default.
• W2007650562 hasConcept C134018914 @default.
• W2007650562 hasConcept C170493617 @default.
• W2007650562 hasConcept C2776885963 @default.
• W2007650562 hasConcept C2777911890 @default.
• W2007650562 hasConcept C2779723316 @default.
• W2007650562 hasConcept C2780192828 @default.
• W2007650562 hasConcept C2780962315 @default.
• W2007650562 hasConcept C502942594 @default.
• W2007650562 hasConcept C61367390 @default.
• W2007650562 hasConcept C71315377 @default.
• W2007650562 hasConcept C71924100 @default.
• W2007650562 hasConcept C98274493 @default.
• W2007650562 hasConceptScore W2007650562C121608353 @default.
• W2007650562 hasConceptScore W2007650562C126322002 @default.
• W2007650562 hasConceptScore W2007650562C134018914 @default.
• W2007650562 hasConceptScore W2007650562C170493617 @default.
• W2007650562 hasConceptScore W2007650562C2776885963 @default.
• W2007650562 hasConceptScore W2007650562C2777911890 @default.
• W2007650562 hasConceptScore W2007650562C2779723316 @default.
• W2007650562 hasConceptScore W2007650562C2780192828 @default.
• W2007650562 hasConceptScore W2007650562C2780962315 @default.
• W2007650562 hasConceptScore W2007650562C502942594 @default.
• W2007650562 hasConceptScore W2007650562C61367390 @default.
• W2007650562 hasConceptScore W2007650562C71315377 @default.
• W2007650562 hasConceptScore W2007650562C71924100 @default.
• W2007650562 hasConceptScore W2007650562C98274493 @default.
• W2007650562 hasIssue "19_Supplement" @default.
• W2007650562 hasLocation W20076505621 @default.
• W2007650562 hasOpenAccess W2007650562 @default.
• W2007650562 hasPrimaryLocation W20076505621 @default.
• W2007650562 hasRelatedWork W1606103292 @default.
• W2007650562 hasRelatedWork W2002807096 @default.
• W2007650562 hasRelatedWork W2058568096 @default.
• W2007650562 hasRelatedWork W2063882679 @default.
• W2007650562 hasRelatedWork W2095873383 @default.
• W2007650562 hasRelatedWork W2104364640 @default.
• W2007650562 hasRelatedWork W24268339 @default.
• W2007650562 hasRelatedWork W2541857854 @default.
• W2007650562 hasRelatedWork W2740124347 @default.
• W2007650562 hasRelatedWork W2772229485 @default.
• W2007650562 hasVolume "74" @default.
• W2007650562 isParatext "false" @default.
• W2007650562 isRetracted "false" @default.
• W2007650562 magId "2007650562" @default.
• W2007650562 workType "article" @default.